Spinal intraarterial chemotherapy: Interim results of a Phase I clinical trial Journal Article
| Authors: | Patsalides, A.; Yamada, Y.; Bilsky, M.; Lis, E.; Laufer, I.; Gobin, Y. P. |
| Article Title: | Spinal intraarterial chemotherapy: Interim results of a Phase I clinical trial |
| Abstract: | OBJECTIVE: Despite advances in therapies using radiation oncology and spinal oncological surgery, there is a subgroup of patients with spinal metastases who suffer from progressive or recurrent epidural disease and remain at risk for neurological compromise. In this paper the authors describe their initial experience with a novel therapeutic approach that consists of intraarterial (IA) infusion of chemotherapy to treat progressive spinal metastatic disease. METHODS: The main inclusion criterion was the presence of progressive, metastatic epidural disease to the spine causing spinal canal compromise in patients who were not candidates for the standard treatments of radiation therapy and/or surgery. All tumor histological types were eligible for this trial. Using the transfemoral arterial approach and standard neurointerventional techniques, all patients were treated with IA infusion of melphalan in the arteries supplying the epidural tumor. The protocol allowed for up to 3 procedures repeated at 3- to 6-week intervals. Outcome measures included physiological measures: 1) periprocedural complications according to the National Cancer Institute's Common Terminology Criteria for Adverse Events; and 2) MRI to assess for tumor response. RESULTS: Nine patients with progressive spinal metastatic disease and cord compression were enrolled in a Phase I clinical trial of selective IA chemotherapy. All patients had metastatic disease from solid organs and were not candidates for further radiation therapy or surgery. A total of 19 spinal intraarterial chemotherapy (SIAC) procedures were performed, and the follow-up period ranged from 1 to 7 months (median 3 months). There was 1 serious adverse event (febrile neutropenia). Local tumor control was seen in 8 of 9 patients, whereas tumor progression at the treated level was seen in 1 patient. CONCLUSIONS: These preliminary results support the hypothesis that SIAC is feasible and safe. ©AANS, 2016. |
| Keywords: | melphalan; oncology; spine; technique; spinal metastasis; intraarterial chemotherapy |
| Journal Title: | Journal of Neurosurgery: Spine |
| Volume: | 24 |
| Issue: | 2 |
| ISSN: | 1547-5654 |
| Publisher: | American Association of Neurological Surgeons |
| Date Published: | 2016-02-01 |
| Start Page: | 217 |
| End Page: | 222 |
| Language: | English |
| DOI: | 10.3171/2015.5.spine14830 |
| PROVIDER: | scopus |
| PUBMED: | 26496162 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 6 December 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work